- Home
- BMRN vs BLSH Comparison
BMRN vs BLSH Comparison
Compare BMRN & BLSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- BLSH
- Stock Information
- Founded
- BMRN 1996
- BLSH 2020
- Country
- BMRN United States
- BLSH Cayman Islands
- Employees
- BMRN N/A
- BLSH N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- BLSH Finance: Consumer Services
- Sector
- BMRN Health Care
- BLSH Finance
- Exchange
- BMRN Nasdaq
- BLSH Nasdaq
- Market Cap
- BMRN 10.5B
- BLSH 10.2B
- IPO Year
- BMRN 1999
- BLSH 2025
- Fundamental
- Price
- BMRN $54.29
- BLSH $38.10
- Analyst Decision
- BMRN Buy
- BLSH Buy
- Analyst Count
- BMRN 19
- BLSH 12
- Target Price
- BMRN $90.26
- BLSH $56.55
- AVG Volume (30 Days)
- BMRN 2.8M
- BLSH 2.2M
- Earning Date
- BMRN 10-27-2025
- BLSH 11-19-2025
- Dividend Yield
- BMRN N/A
- BLSH N/A
- EPS Growth
- BMRN 59.53
- BLSH N/A
- EPS
- BMRN 2.68
- BLSH N/A
- Revenue
- BMRN $3,094,001,000.00
- BLSH $166,608,000.00
- Revenue This Year
- BMRN $13.32
- BLSH $72.66
- Revenue Next Year
- BMRN $7.51
- BLSH $35.48
- P/E Ratio
- BMRN $20.20
- BLSH N/A
- Revenue Growth
- BMRN 12.39
- BLSH 70.05
- 52 Week Low
- BMRN $50.76
- BLSH $36.02
- 52 Week High
- BMRN $73.51
- BLSH $118.00
- Technical
- Relative Strength Index (RSI)
- BMRN 53.35
- BLSH N/A
- Support Level
- BMRN $53.67
- BLSH N/A
- Resistance Level
- BMRN $55.34
- BLSH N/A
- Average True Range (ATR)
- BMRN 1.49
- BLSH 0.00
- MACD
- BMRN 0.28
- BLSH 0.00
- Stochastic Oscillator
- BMRN 78.60
- BLSH 0.00
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.